Wuxi AppTec Co (FRA:WX8) EBIT: ¥25,505 Mil (TTM As of Mar. 2026)


FRA:WX8 Wuxi AppTec Co Ltd FRA:WX8
96 GF Score
Price ¥16.01
GF Value ¥11.53
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Wuxi AppTec Co EBIT?

Wuxi AppTec Co FRA:WX8 -0.06% 96 EBIT is ¥25,505 Mil as of Mar. 2026. GuruFocus rates FRA:WX8 with a GF Score™ of 96/100 and a GF Value™ of ¥11.53 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Wuxi AppTec Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥5,638 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥25,505 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wuxi AppTec Co's annualized ROC % for the quarter that ended in Mar. 2026 was 32.18%. Wuxi AppTec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 66.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wuxi AppTec Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.92%.

Wuxi AppTec Co  (FRA:WX8) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wuxi AppTec Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=20433.864 * ( 1 - 16.71% )/( (51803.096 + 53985.36)/ 2 )
=17019.3653256/52894.228
=32.18 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=103120.969 - 10380.352 - ( 40937.521 - max(0, 19235.268 - 61677.056+40937.521))
=51803.096

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=107414.481 - 10044.662 - ( 43384.459 - max(0, 19041.486 - 65169.309+43384.459))
=53985.36

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Wuxi AppTec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=22552.932/( ( (26638.565 + max(6437.269, 0)) + (26956.908 + max(8003.832, 0)) )/ 2 )
=22552.932/( ( 33075.834 + 34960.74 )/ 2 )
=22552.932/34018.287
=66.30 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7262.654 + 8993.245 + 3270.881) - (10380.352 + 0 + 2709.159)
=6437.269

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7700.937 + 9965.88 + 3236.669) - (10044.662 + 0 + 2854.992)
=8003.832

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wuxi AppTec Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=25505.222/322123.784
=7.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuxi AppTec Co EBIT Related Terms

Wuxi AppTec Co EBIT Historical Data

* Premium members only.

The historical data trend for Wuxi AppTec Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuxi AppTec Co EBIT Chart

Wuxi AppTec Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,143.94 10,778.31 12,025.57 11,808.38 24,212.64

Wuxi AppTec Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,345.66 5,730.57 5,187.55 8,948.86 5,638.23

FRA:WX8 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuxi AppTec Co EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's EV-to-EBIT falls into.


FRA:WX8
96GF Score
Wuxi AppTec Co Ltd FRA:WX8
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuxi AppTec Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥25,505 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥25,505 Mil mean?
Wuxi AppTec Co (FRA:WX8) has a EBIT of ¥25,505 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Wuxi AppTec Co.
Is Wuxi AppTec Co's EBIT too high?
Wuxi AppTec Co's current EBIT is ¥25,505 Mil. Overall, Wuxi AppTec Co has a GF Score™ of 96/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EBIT compare to TMO and DHR?
Wuxi AppTec Co's EBIT of ¥25,505 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Wuxi AppTec Co. Wuxi AppTec Co's current EBIT is ¥25,505 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (FRA:WX8) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥11.53, compared to a current price of ¥16.01 — trading 38.8% above its estimated fair value. The current EBIT is ¥25,505 Mil. Wuxi AppTec Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Wuxi AppTec Co (FRA:WX8), the current EBIT is ¥25,505 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wuxi AppTec Co (FRA:WX8) Overvalued in 2026?

Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued. The current stock price of ¥16.01 is trading 38.8% above its estimated GF Value™ of ¥11.53. GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.

Key valuation signals for FRA:WX8:

  • EBIT: ¥25,505 Mil
  • GF Value™: ¥11.53 vs. price of ¥16.01 (38.8% above fair value)
  • GF Score™: 96/100 with 4 warning signs

No single metric tells the full story. See the FRA:WX8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wuxi AppTec Co Business Description

Address 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
96GF Score

Get the complete analysis for FRA:WX8

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.01
Price
¥11.53
GF Value